AEROGEN INC Form 10-Q/A April 18, 2005

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 10-Q/A

(Mark One)
\circ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended June 30, 2004
OR
o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from to
Commission File Number: 0-31913

Aerogen, Inc.

(Exact name of Registrant as specified in its charter)

Delaware

33-0488580

(State or other jurisdiction of incorporation or organization)

(I.R.S. Employer Identification No.)

2071 Stierlin Court, Suite 100, Mountain View, CA

(Address of principal executive offices)

94043 (zip code)

Registrant s telephone number, including area code: (650) 864-7300

Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 (the Exchange Act) during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes ý No o

Indicate by check mark whether the Registrant is an accelerated filer (as defined in Rule 12b-2 of the Exchange Act): Yes o No \acute{y}

As of August 2, 2004, there were 4,784,506 shares of the Registrant's Common Stock, par value \$0.001, outstanding.

EXPLANATORY NOTE

The purpose of this Amendment No. 1 to Aerogen s Form 10-Q for the quarter ended June 30, 2004 is to restate our financial statements to correct an error in the accounting for warrants to purchase common stock issued during fiscal 2004 as further discussed in Note 2 to the condensed consolidated financial statements. No attempt has been made in the Form 10-Q/A to modify or update any disclosures except as required to reflect the impact of this restatement.

Aerogen, Inc.

Form 10-Q

Table of Contents

<u>Part I.</u>	Financial Information	
	Item 1.	Condensed Consolidated Financial Statements (unaudited)
		Condensed Consolidated Balance Sheets as of June 30, 2004 and December 31, 2003
		Condensed Consolidated Statements of Operations for the three and six months ended June 30, 2004 and 2003
		Condensed Consolidated Statements of Cash Flows for the six months ended June, 2004 and 2003
		Notes to Condensed Consolidated Financial Statements
	Item 2.	Management s Discussion and Analysis of Financial Condition and Results of Operations
	Item 3.	Quantitative and Qualitative Disclosures About Market Risk
	<u>Item 4.</u>	Controls and Procedures
<u>Part II.</u>	Other Information	
	Item 1.	Legal Proceedings
	Item 2.	<u>Changes in Securities</u> , <u>Use of Proceeds and Issuer Purchases of Equity Securities</u>
	Item 3.	<u>Defaults Upon Senior Securities</u>
	<u>Item 4.</u>	Submission of Matters to a Vote of Security Holders
	<u>Item 5.</u>	Other Information
	Item 6.	Exhibits and Reports on Form 8-K
<u>Signatures</u>		
		2.

Part I. Financial Information

Item 1. Condensed Consolidated Financial Statements

Aerogen, Inc.

Condensed Consolidated Balance Sheets

(unaudited; in thousands, except per share data)

	June 30, 2004 (Restated)	December 31, 2003
ASSETS		
Current assets:		
Cash and cash equivalents	\$ 24,821	\$ 762
Accounts receivable	972	445
Inventories, net	569	301
Prepaid expenses and other current assets	721	428
Total current assets	27,083	1,936
Property and equipment, net	2,954	3,901
Goodwill and other intangible assets, net	1,858	1,931
Restricted cash		1,200
Other assets	583	608
Total assets	\$ 32,478	\$ 9,576
LIABILITIES, REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS EQUITY (DEFICIT) Current liabilities:		
Accounts payable	\$ 554	\$ 937
Deferred revenue, current	961	500
Convertible debentures, net		1,486
Accrued liabilities	1,347	1,194
Total current liabilities	2,862	4,117
Deferred rent	174	1,658
Deferred revenue, non-current	2,002	1,875
Warrant liability	17,558	,
Other long-term liabilities	236	246
Total liabilities	22,832	7,896
Redeemable convertible preferred stock		
Redeemable convertible preferred stock, par value \$0.001: Authorized: 5,000 shares; issued and outstanding: 1,142 shares at June 30, 2004 and no shares at December 31, 2003, respectively) (Liquidation		
preference: \$34,260 at June 30, 2004)	16,351	
Stockholders equity (deficit):	-	4
Common stock, par value \$0.001: Authorized: 95,000 shares; issued and outstanding:	5	4

4,785 shares at June 30, 2004 and 4,396 shares at December 31, 2003		
Additional paid-in capital	111,779	110,991
Notes receivable from stockholders	(286)	(280)
Deferred stock-based compensation, net	(48)	(264)
Accumulated other comprehensive income	886	700
Accumulated deficit	(119,041)	(109,471)
Total stockholders equity (deficit)	(6,705)	1,680
Total liabilities, redeemable convertible preferred stock and stockholders equity (deficit)	\$ 32.478 \$	9,576

The accompanying notes are an integral part of these condensed consolidated financial statements.

Aerogen, Inc.

Condensed Consolidated Statements of Operations

(unaudited; in thousands, except per share data)

	Three Months Ended June 30,			Six Months Ended June 30,		
	2004 estated)	,	2003	2004 (Restated)	2003	
Revenues:	Ź			· /		
Product sales	\$ 1,251	\$	989 \$	2,100		